申请人:Vernalis (R&D) Ltd.
公开号:US09006269B2
公开(公告)日:2015-04-14
Compounds of formula (I) are inhibitors of fatty acid amide hydrolase, (FAAH), and which are useful in the treatment of diseases or medical conditions which benefit from inhibition of FAAH activity, such as anxiety, depression pain, inflammation, and eating, sleep, neurodegenerative and movement disorders:
Wherein Ar1 is optionally substituted phenyl or optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms; Ar2 is optionally substituted phenyl, optionally substituted monocyclic heteroaryl having 5 or 6 ring atoms or optionally substituted fused bicyclic heteroaryl having 5 or 6 ring atoms in each fused ring; and Ar3 is a divalent radical selected from the group consisting of optionally substituted phenylene and optionally substituted monocyclic heteroarylene radicals having 5 or 6 ring atoms.
式(I)的化合物是脂肪酸酰胺水解酶(FAAH)的抑制剂,对于需要抑制FAAH活性的疾病或医疗状况具有治疗作用,例如焦虑、抑郁、疼痛、炎症、进食、睡眠、神经退行性和运动障碍:
其中Ar1是可以选择性取代的苯基或具有5或6个环原子的可以选择性取代的单环杂芳基;Ar2是可以选择性取代的苯基,具有5或6个环原子的可以选择性取代的单环杂芳基或在每个融合环中具有5或6个环原子的可以选择性取代的融合双环杂芳基;Ar3是从包括可以选择性取代的苯撑基和具有5或6个环原子的可以选择性取代的单环杂芳撑基的基团中选择的二价基团。